RR6 Model

RR6 Calculator

The RR6 model predicts survival in myelofibrosis based on clinical response after 6 months of ruxolitinib.

Reference

Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, Polverelli N, Rumi E, Caramella M, Carraro MC, D'Adda M, Molteni A, Sissa C, Lunghi F, Vismara A, Ubezio M, Guidetti A, Caberlon S, Anghilieri M, Komrokji RS, Cattaneo D, Della Porta MG, Giorgino T, Bertu L, Brociner M, Kuykendall AT, Passamonti F. A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients with Myelofibrosis. Blood Advances 2022. bloodadvances.2021006889. doi:10.1182/bloodadvances.2021006889

IMPORTANT: This tool is for educational use only. It does not constitute medical advice. It should not be used for medical diagnosis and/or medical treatment.

Data at baseline

Evaluation at ruxolitinib start

Spleen length (cm below LCM) Total daily ruxolitinib dose (mg) 0 mg

E.g.: 20 mg BID = 40 mg total daily dose

RBC transfusions in the previous 3 months not performed performed

Data at 3 months

Evaluation 3 months after ruxolitinib start

Spleen length (cm below LCM) Total daily ruxolitinib dose (mg) 0 mg

E.g.: 20 mg BID = 40 mg total daily dose

RBC transfusions since baseline not performed performed

Data at 6 months

Evaluation 6 months after ruxolitinib start

Spleen length (cm below LCM) Total daily ruxolitinib dose (mg) 0 mg

E.g.: 20 mg BID = 40 mg total daily dose

RBC transfusions since the 3-month visit not performed performed

RR6 model results

Risk stratum: IR - Intermediate
Median overall survival*: 61 months
Median o. survival* 95% CI: 43-80 months

*counted from 6 months post ruxolitinib start.

Calculation

Risk points:

spleen length reduction <=30%: 0
low ruxolitinib dose: 1
transfusion status: 0

Total risk points: 1

Legend

LCM - left costal margin

BID - bis in die, twice daily

RBC - red blood cell

Survival curves

Actuarial survival curves of the 3 risk groups of patients according to the Response to Ruxolitinib after 6 months (RR6) developed in ruxolitinib-treated myelofibrosis patients (training cohort).

Source: Maffioli et al., A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients with Myelofibrosis. Blood Advances. doi:10.1182/bloodadvances.2021006889